Year-end report 2007

• Biotage reports an operating result for the full year 2007 amounting to 42.9 MSEK (6.5 MSEK last year). The positive development of the operating result continued also in the fourth quarter and the result amounted to 15.3 MSEK (9.4).

• The result after taxes amounted to 99.4 MSEK (2.8) for the full year and to 42.9 MSEK (11.0) in the fourth quarter. During the year capitalization of deferred income taxes recoverable was made to the amount of 54.1 MSEK and to the amount of 25.8 MSEK in the fourth quarter.


• Net sales amounted to 496.4 MSEK (519.5) in the full year 2007 and to 134.5 MSEK (136.6) in the fourth quarter. At comparable exchange rates and excluding the Chem Dev product area the sales increase was 3 percent in the full year and 8 percent in the fourth quarter.

• Earnings per share amounted to 1.12 SEK (0.03) for the full year and to 0.48 SEK (0.12) for the fourth quarter.


Comments from CEO Torben Jörgensen
In the fourth quarter we have achieved the best operating result ever for Biotage, 15.3 MSEK. The operating margin for the fourth quarter amounted to 11.4 percent. For the full year the operating result amounted to 42.9 MSEK, with an operating margin of 8.6 percent, a substantial improvement compared to previous years. The result after taxes amounted to 99.4 MSEK. Of this sum, 54.1 MSEK relates to capitalization of deferred income taxes recoverable. The positive result development has thus made it possible to start utilize the Group’s large loss carry forward, which is in the magnitude of 1,000 MSEK.
In the fourth quarter sales recovered well after a slow third quarter, at a comparable basis by 8 percent compared to the same period 2006.

In 2006 and 2007 we have devoted much energy to the integration and consolidation of earlier acquisitions with the objective to create a profitable company, which we now have achieved. Therefore we can now shift focus to organic growth with an improved operating margin. Heavy investments have been made in developing new competitive products in both business areas and we are therefore now ready to launch several new major products in the first half of 2008. We will also launch a number of new consumables and product upgrades during the year.

The strategic review undertaken by Biotage is progressing according to plan. A number of interesting, potential industrial partners have been identified and different alternatives are being investigated.

For further information, please contact:
Torben Jörgensen, president and CEO, phone: +46 707 49 05 84
Mats-Olof Wallin, CFO, phone: +46 705 93 52 73